Skip to Content

Late-breaking from ASH22 – Zanubrutinib has now proven superiority to ibrutinib

The ALPINE study is the first study to demonstrate a superior Progression-Free Survival (PFS) and safety profile of zanubrutinib compared to ibrutinib in patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL).

Få tilgang til artikkelen

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top